Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars. The commentary below focuses on continuing operations including the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. 2019 – delivering on our strategy, producing strong finan - cial results, and making a significant impact on society by improving and extending the lives of people across the globe. La Belgique est l'un des nombreux pays à bénéficier de ce don. Boucherville, December 17, 2020 – Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz ® (adalimumab injection, reference biologic drug: Humira ®) on November 4, 2020 for marketing in … Novartis continues to expect the previously-announced divestment of the Sandoz US oral solids and dermatology portfolio to be completed during 2019, pending closing conditions including regulatory approvals. This presentation remains on the Novartis website for historical purposes only. Torrent Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. [5]  Discontinued operations described on page 32 of the Condensed Interim Financial Report. Novartis revenue breakdown by geographic segment: 5.6% from Japan , 34.3% from United States, 5.1% from France, 8.7% from Germany and 46.3% from Other A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Novartis website. L'ensemble des spécialités précitées contenant les notices actualisées sont désormais disponibles. Our strategy is to focus Novartis as a leading medicines company with five priorities: embrace operational excellence, deliver transformative innovation, go big on data science, build trust with society, and build a new culture by unleashing the power of our people. Free cash flow amounted to USD 1.9 billion broadly in line with the prior year, which included the receipt of a sales milestone related to the Vaccines divestment to GSK. The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2019. calcul de leur revenu imposablefédéral et provincial pour l'année d'imposition 2019. This reduced the net debt position of Novartis by approximately USD 3.0 billion. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. Novartis has appointed Richard Saynor as CEO of Sandoz effective no later than August 1, 2019. Boston, January 7, 2019 – Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). Forecast assumption that no Gilenya generics enter in 2019; however, generic competitors may still launch at risk. PDF document. Operating income was USD 71 million compared to USD 76 million in prior year, mainly as higher sales, as well as the discontinuation of amortization and depreciation as of March 1 (USD 118 million), were offset by higher one-time costs relating to the spin-off, higher legal costs and growth investments. EPS was USD 0.81 (-5%, +5% cc) in line with net income. Core operating income amounted to USD 350 million for discontinued operations (-3%, +7% cc) as higher sales and gross margin, as well as discontinuation of depreciation and software amortization from March 1 (USD 30 million) were partly offset by growth investments. An explanation of non-IFRS measures can be found on page 41 of the Condensed Interim Financial Report. Richard has also built and led successful teams and organizations with a strong focus on inclusive culture and developing talent. Please find full media release in English attached and on the following link:http://hugin.info/134323/R/2242311/884922.pdf. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. The results of this business are included in continuing operations until the time of the divestment. Renseignements : Paule Pelletier Sandoz Canada Inc. +1 514 702-7699 paule.pelletier@sandoz.com / communications.canada@sandoz.com Ces communiqués peuvent vous intéresser aussi 31 déc 2020 TOP 10 PHARMACEUTICAL COMPANIES BY REVENUES: JOHNSON AND JOHNSON: $82.1 billion ROCHE: $63.3 billion PFIZER: $51.75 billion NOVARTIS: $47.45 billion MERCK: $46.84 billion GSK: $ 43.92 billion SANOFI: $39.28 billion ABBVIE: $33.27 billion ABBOTT: $31.90 billion TAKEDA: 31.17 billion Other major pharma companies are: BMS • La législation canadienne en matière d’impôt sur le revenu permet à un contribuable de différer l’impôt sur le dividende en nature si un choix est produit. In particular, our expectations could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the proposed transactions or the development of the products described in this release; the potential that the strategic benefits, synergies or opportunities expected from the Alcon and Sandoz transactions may not be realized or may be more difficult or take longer to realize than expected; the inherent uncertainties involved in predicting shareholder returns; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and will continue this year; safety, quality or manufacturing issues; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential litigation with respect to the proposed transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally; uncertainties involved in the development or adoption of potentially transformational technologies and business models; our performance on environmental, social and governance measures; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. [1]  Constant currencies (cc), core results and free cash flow are non-IFRS measures. Prior to GSK, Richard held Commercial Operations leadership roles at Sandoz and oversaw a strong expansion of Sandoz' generics business across Asia, Latin America and Turkey. As Narasimhan outlined, Novartis’ key strategic goals for Sandoz include achieving a profile that delivers low-to-mid single digit revenue growth; with core margins and core returns on sales in the mid-to-high 20s. Retaining a good balance between investment in the business, a strong capital structure and attractive shareholder returns remains a priority. Notre mission au sein du groupe Novartis est de mettre à la disposition du plus grand nombre des médicaments de qualité à un prix plus abordable. About 105,000 people of more than 140 nationalities work at Novartis around the world. The digital and interactive version of the Annual Review is available here. Net loss from discontinued operations amounted to a loss of USD 101 million compared to a net income of USD 58 million in prior year mainly due to higher one-time tax expenses. Net sales in 2019 are expected to grow mid-single digit (cc). This is a decrease of some four billion U.S. dollars compared to the year before. Pricing had a negative impact of 1 percentage point (cc). Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. During his career, Richard has established a successful track record building strong interfaces between commercial and technical operations as well as driving commercial excellence across his organization. Core operating income margin in constant currencies increased by 2.6 percentage points; currency had a negative impact of 0.6 percentage points, resulting in a net increase of 2.0 percentage points to 29.3% of net sales. A replay will be available after the live webcast by visiting.https://www.novartis.com/investors/event-calendar, Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below. Revenue: In the first quarter of 2019, the Company recorded $2.4 million in product revenue from Sandoz’s sales of Glatopa, net of a deduction of $1.5 million for legal settlement and royalty payments to Teva Pharmaceutical Industries. In the same quarter, 13.8 million shares (for an equity value of USD 0.5 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. En complément de notre communication en date du 20 décembre 2019 et du 9 janvier 2020, nous vous informons que les spécialités Amoxicilline SANDOZ 1 g, comprimé dispersible (boîtes de 6 et de 14 comprimés) contenant la notice actualisée sont désormais disponibles. [2]  Refers to continuing operations as defined on page 32 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. The spin-off allows shareholders to benefit from a standalone Alcon and a Novartis with capital and management attention fully focused on medicines. Additional information is provided on Novartis divisions and pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found at.https://www.novartis.com/investors/event-calendar. « Sandoz se consacre à accroître son portfolio de biosimilaires au Canada et Hyrimoz ... mènent à une substitution non médicale obligatoire et qui auraient été introduites dans toutes les provinces en 2019 (étanercept et infliximab seulement) pourraient générer 239,6 M$ en économies nationales. Sandoz Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. In order to comply with International Financial Reporting Standards (IFRS), Novartis has separated the Group's reported financial data for the current and prior years into "continuing" and "discontinued" operations. Innovative Medicines net sales were USD 8.8 billion (+5%, +10% cc) in the first quarter, as Pharmaceuticals BU grew 11% (cc) mainly driven by Cosentyx and Entresto, and Oncology BU grew 9% (cc) mainly driven by Lutathera, Promacta and Kisqali. We enter an exciting period with expected launches of Zolgensma, BYL719 and brolucizumab and multiple late stage readouts. Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results. Core EPS was USD 1.21 (+5%, +13% cc) in line with core net income. As of March 31, 2019, the net debt increased by USD 5.3 billion to USD 21.5 billion versus December 31, 2018. 2018. The Sandoz pocket book provides a comprehensive overview of our company, our business areas, corporate responsibility work and information about Sandoz as an employer of choice. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. The Corporate Fact Sheets provide a comprehensive overview of Novartis overall as well as our divisions (Innovative Medicines, Sandoz), our research organization NIBR, and outline our commitment to associates as well as Corporate Responsibility. Revenue Annual and half yearly information News & announcement Next. Among other headlines last year, Amgen beat back a patent challenge from Novartis' Sandoz on blockbuster immunology drug Enbrel. 10.2.2 Sandoz Description, Business Overview and Total Revenue 10.2.3 Sandoz Megestrol Sales, Revenue and Gross Margin (2015-2020) 10.2.5 Sandoz Recent Development Sandoz is focused on therapies for Cardiovascular, CNS, Dermatology, Gastrointestinal & Hormonal disorders, Metabolism, Oncology, Ophthalmic pain, and Respiratory disorders. Generic competition had a negative impact of 1 percentage point (cc). [6]  The brand name Zolgensma has been provisionally approved by the FDA for the investigational product AVXS-101 (onasemnogene abeparvovec-xioi), but the product itself has not received marketing authorization or BLA approval from any regulatory authorities. Regulated information Regulated information ... 2019: Strong results and a successful transformation. Free cash flow was €6.1 billion in 2019, up from €5.4 billion in the prior year. 2019 à 19 ... elles représentent un complément de revenu pour le trentenaire. reSET-O, cleared by the US Food and Drug Administration (FDA) in December, is immediately available. Novartis aims to offset the dilutive impact from equity based participation plans of associates over the remainder of the year. Excluding the US, net sales grew 4% (cc). Richard is a Pharmacist by training and started his pharma business career as a sales representative at G.D. Searle in the U.K. Underpinning our financial results in the first quarter is a continued focus on key growth drivers including: Net sales of the top 20 Innovative Medicines products in Q1, Strengthen R&D - Key developments from the first quarter, Results from ongoing trials and other highlights. As of Q1 2019, the long-term credit rating for the company is A1 with Moody's Investors Service and AA- with S&P Global Ratings. 339 kb EN Invitation Full-Year 2019 Results. According to this study, over the next five years the Donepezil market will register a -1.6% CAGR in terms of revenue, the global market size will reach US$ 830 million by 2024, from US$ 920 million in 2019. Half yearly information. Novartis remains fully committed to this business until it is divested to Aurobindo. Novartis revenue breakdown by business segment: 20.5% from Sandoz and 79.5% from Innovative Medicines. Bâle, le 16 juillet 2020 - Sandoz a annoncé aujourd’hui une nouvelle opération visant à faciliter aux patients des pays à faible revenu (PFR) et à revenu intermédiaire inférieur (PRITI) l’accès à des médicaments à des prix abordables pour traiter les principaux symptômes du COVID-19, un besoin essentiel en l’absence de vaccin ou de traitement curatif. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie du COVID-19. At the beginning of 2019, ... Sandoz Targets 40 First-To-File Opportunities In The US. * Hyrimoz® approved for use in all same indications as reference medicine* including rheumatology, gastroenterology and dermatology. Global sales of Biopharmaceuticals grew 11% (cc) driven by Europe with continued strong double-digit growth from Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi (etanercept). Core net income was USD 2.8 billion (+5%, +13% cc) as growth in core operating income was partly offset by the discontinuation of core income from the GSK consumer healthcare joint venture. In 2019, Novartis AG made approximately 38.5 billion U.S. dollars from its pharmaceuticals business segment. Balance sheet impacts of the Alcon spin off will be included in the second quarter results. Strong volume growth was partly offset by the negative impacts of pricing (-3 percentage points cc) and generic competition (-1 percentage point cc). Le choix en question est … [1] Continuing operations include the businesses of Innovative Medicines and Sandoz divisions and Corporate activities and discontinued operations include the business of Alcon. Net income was USD 1.9 billion, (-5%, +4% cc) broadly in line with operating income. Volume contributed 12 percentage points (cc) to sales growth. The increase was mainly driven by the USD 6.6 billion annual dividend payment, partly offset by USD 1.9 billion free cash flow from continuing operations in Q1 2019.